ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pembrolizumab

Also written as “Pembrolizumab”, “Pembrolizumab 200 mg” and “NGM707 plus pembrolizumab (KEYTRUDA®)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Squamous Cell Carcinoma of Head and Neck · Stomach Neoplasms · Urinary Bladder Neoplasms, led by 8 companies.

Drug pagePembrolizumab: every studyMany companies study it; this page follows only the 148 they lead. All 1,133 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 19, 2018148 company-led studies, 27 open or runningNext primary completion: Nov 20, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only13824 open or runningphase 4since Oct 19, 2018Feb 10, 2011Nov 20, 2026phase 3 · NCT04634877
Novartisits history only30 open or runningphase 2since May 15, 2019Dec 12, 2013none ahead
PDS Biotechnologyits history only20 open or runningphase 3since Jan 14, 2025Feb 5, 2020none ahead
AGO Researchits history only11 open or runningphase 2since May 11, 2023May 11, 2023Oct 30, 2027phase 2 · NCT05903833
EverNov Medicines (Zhuhai Hengqin)its history only10 open or runningphase 2since Dec 29, 2020Dec 29, 2020none ahead
Mediclinic Middle Eastits history only10 open or runningphase 2since Mar 14, 2019Mar 14, 2019none ahead
NovoCureits history only11 open or runningphase 3since Aug 13, 2024Aug 13, 2024Apr 2029phase 3 · NCT06556563
TiumBio11 open or runningphase 2since Feb 20, 2023Feb 20, 2023Dec 2026phase 2 · NCT05784688

Also a collaborator on its studies: Eisai, Pfizer, Astellas Pharma, Novotech (Australia) Pty and Medidata Solutions.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of TiumBio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 20, 2023First study: phase 2 study in Biliary Tract NeoplasmsFirst studyNCT05784688 · 140 planned · United States, Korea, Republic of

Ahead

  1. Dec 2026Primary completion: phase 2 study in Biliary Tract NeoplasmsNCT05784688

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The one study TiumBio leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05784688Biliary Tract Neoplasms · United States, Korea, Republic of2RecruitingDec 2026140

How it is read

Names in the registry

  • “Pembrolizumab”, 124 entries
  • “pembrolizumab”, 29 entries
  • “Pembrolizumab 200 mg”, 7 entries
  • “NGM707 plus pembrolizumab (KEYTRUDA®)”, 4 entries
  • “GV20-0251 and Pembrolizumab [KEYTRUDA®]”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.